<DOC>
	<DOCNO>NCT02875067</DOCNO>
	<brief_summary>This trial ass safety &amp; efficacy Combination Pembrolizumab Lenalidomide management patient Relapsed Hodgkin Lymphoma .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Combination Pembrolizumab Lenalidomide , Patients With Relapsed Non-Hodgkin Hodgkin Lymphoma</brief_title>
	<detailed_description>There emerge clinical data confirm Programmed death-1 ( PD-1 ) blockade safe viable lymphoma . The investigator hypothesize novel immune platform pembrolizumab lenalidomide , safe well tolerated patient Relapsed Refractory ( RR ) Hodgkin Lymphoma ( HL ) non-Hodgkin lymphoma ( NHL ) combination result complete response ( CR ) rate 50 % patient RR HL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Be willing able provide write informed consent/assent trial . 2 . Be 18 year age day sign informed consent . 3 . Have measurable evaluable disease , defined 2007 Revised Response Criteria Malignant Lymphoma24 receive least two prior therapy . HL patient must currently eligible autologous stem cell transplant . 4 . Be willing provide either archived tumor tissue tissue newly obtain core excisional biopsy tumor lesion . Newlyobtained defined specimen obtain 6 week ( 42 day ) prior initiation treatment Day 1 . 5 . Have performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . 6 . Demonstrate adequate organ function define Table 1 , screen lab perform within 14 day treatment initiation . Adequate Organ Function Laboratory Values : Absolute neutrophil count ( ANC ) : ≥1,000 /microliter ( mcL ) Platelets : ≥75,000 / mcL Hemoglobin : ≥9 g/dL ≥5.6 mmol/L without transfusion erythropoietin ( EPO ) dependency ( within 7 day assessment ) Serum creatinine OR : ≤1.5 X upper limit normal ( ULN ) OR Measured calculate creatinine clearance ( GFR also use place creatinine CrCl ) : ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Serum total bilirubin : ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level : &gt; 1.5 ULN Aspartate aminotransferase ( AST ) / serum glutamic oxaloacetic transaminase ( SGOT ) alanine aminotransferase ( ALT ) / serum glutamic pyruvic transaminase ( SGPT ) : ≤ 2.5 X ULN OR ≤ 5 X ULN subject liver metastasis Albumin : &gt; 2.5 mg/dL International Normalized Ratio ( INR ) Prothrombin Time ( PT ) : ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Activated Partial Thromboplastin Time ( aPTT ) : ≤1.5 X ULN unless subject receive anticoagulant therapy , long PT PTT within therapeutic range intend use anticoagulant aCreatinine clearance calculate per institutional standard . 7 . Female subject childbearing potential two negative urine serum pregnancy test , one 1014 day first dose study drug another within 24 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 8 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 9 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 1 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has know history active Bacillus Tuberculosis ( TB ) 4 . Hypersensitivity pembrolizumab excipients . 5 . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 6 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 7 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 8 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . 9 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 10 . Has know history , evidence active , noninfectious pneumonitis . 11 . Has active infection require systemic therapy . 12 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 13 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 14 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial treatment . 15 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . 16 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 17 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C virus ( HCV ) ( e.g. , HCV Ribonucleic acid ( RNA ) [ qualitative ] detect ) , active viral hepatitis . Patients treat resolved hepatitis B C eligible . Patients active liver disease , except liver abnormality directly attributable lymphoma ineligible , 18 . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>